TransMedics Group, Inc. (NASDAQ:TMDX) Receives $174.30 Consensus PT from Brokerages

TransMedics Group, Inc. (NASDAQ:TMDX) has earned an average rating of “Buy” from the eleven analysts that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation, nine have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $174.30.

TMDX has been the subject of a number of recent analyst reports. Stephens boosted their price target on shares of TransMedics Group from $151.00 to $178.00 and gave the company an “overweight” rating in a research report on Friday, August 2nd. Piper Sandler reaffirmed an “overweight” rating and set a $180.00 price objective on shares of TransMedics Group in a report on Monday, October 7th. Canaccord Genuity Group lifted their price objective on shares of TransMedics Group from $117.00 to $169.00 and gave the stock a “buy” rating in a report on Thursday, August 1st. Oppenheimer lifted their price objective on shares of TransMedics Group from $125.00 to $200.00 and gave the stock an “outperform” rating in a report on Thursday, August 1st. Finally, Robert W. Baird assumed coverage on shares of TransMedics Group in a report on Tuesday, September 24th. They set an “outperform” rating and a $200.00 price objective for the company.

Insider Buying and Selling at TransMedics Group

In other TransMedics Group news, insider Tamer I. Khayal sold 2,958 shares of the business’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $156.77, for a total value of $463,725.66. Following the transaction, the insider now owns 20,843 shares in the company, valued at approximately $3,267,557.11. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other TransMedics Group news, insider Tamer I. Khayal sold 2,958 shares of the business’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $156.77, for a total value of $463,725.66. Following the transaction, the insider now owns 20,843 shares in the company, valued at approximately $3,267,557.11. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Waleed H. Hassanein sold 8,625 shares of the business’s stock in a transaction dated Monday, July 15th. The shares were sold at an average price of $145.17, for a total transaction of $1,252,091.25. Following the completion of the transaction, the chief executive officer now owns 61,643 shares in the company, valued at $8,948,714.31. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 64,205 shares of company stock worth $10,089,374. 7.00% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On TransMedics Group

Several hedge funds and other institutional investors have recently modified their holdings of TMDX. First Light Asset Management LLC increased its position in shares of TransMedics Group by 22.0% during the fourth quarter. First Light Asset Management LLC now owns 754,317 shares of the company’s stock valued at $59,538,000 after buying an additional 136,217 shares during the period. Osterweis Capital Management Inc. increased its position in shares of TransMedics Group by 78.5% during the fourth quarter. Osterweis Capital Management Inc. now owns 64,565 shares of the company’s stock valued at $5,096,000 after buying an additional 28,390 shares during the period. Goldman Sachs Group Inc. increased its position in shares of TransMedics Group by 10.9% during the fourth quarter. Goldman Sachs Group Inc. now owns 397,283 shares of the company’s stock valued at $31,358,000 after buying an additional 38,951 shares during the period. Vanguard Group Inc. increased its position in shares of TransMedics Group by 2.8% during the fourth quarter. Vanguard Group Inc. now owns 1,865,115 shares of the company’s stock valued at $147,214,000 after buying an additional 50,673 shares during the period. Finally, HighPoint Advisor Group LLC purchased a new position in shares of TransMedics Group during the fourth quarter valued at about $603,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

TransMedics Group Stock Down 0.5 %

TMDX opened at $135.19 on Thursday. The company has a fifty day moving average price of $155.20 and a 200-day moving average price of $135.90. The firm has a market capitalization of $4.51 billion, a P/E ratio of 3,379.75 and a beta of 1.99. The company has a debt-to-equity ratio of 2.67, a current ratio of 9.37 and a quick ratio of 8.48. TransMedics Group has a one year low of $36.42 and a one year high of $177.37.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings results on Wednesday, July 31st. The company reported $0.35 EPS for the quarter, beating analysts’ consensus estimates of $0.21 by $0.14. The firm had revenue of $114.30 million during the quarter, compared to analyst estimates of $98.84 million. TransMedics Group had a net margin of 0.84% and a return on equity of 15.98%. The business’s revenue for the quarter was up 117.7% on a year-over-year basis. During the same period in the previous year, the business earned ($0.03) EPS. Equities research analysts expect that TransMedics Group will post 1.22 earnings per share for the current fiscal year.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.